Today: 23 June 2026
Browse Category

Pharmaceuticals 31 January 2026 - 3 February 2026

AbbVie is acquiring Apogee Therapeutics for $135.11 per share in cash, valuing Apogee at about $10.9 billion. The deal is expected to close in the third quarter and will bring AbbVie zumilokibart, an experimental long-acting drug for atopic dermatitis and other immune diseases. Apogee claims its top eczema drug could significantly reduce injection frequency compared to Dupixent, with Phase 3 trials planned for this year. Pfizer shares declined over the past week after CFO Dave Denton announced he will step down in August, with Cecile Guegan set to become interim CFO. Despite the leadership change, Pfizer maintained its 2026 forecast, but investors remain focused on succession, execution, and competition from obesity-drug makers. Pfizer’s stock has also been affected by concerns over pricing pressure, patent cliffs, and a longer path to profitability in obesity drugs. Meanwhile, Novo Nordisk shares rose about 5% as healthcare stocks gained favor among investors seeking defensive positions, even as the company reported strong demand for its Wegovy pill. Alumis shares surged 15.55% ahead of Phase 2b lupus results due in the third quarter and a planned psoriasis NDA filing in the fourth quarter. Outlook Therapeutics shares jumped 30% after the FDA accepted its resubmitted application for ONS-5010/LYTENAVA, with a key FDA decision expected on July 29. Other notable moves include AtaiBeckley’s 7.8% rise following the start of its BPL-003 Phase 3 program and CervoMed’s premarket jump after a director-linked trust purchased $3 million in units, following a recent $10.5 million private placement.
Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings

Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings

Eli Lilly shares fell 1.4% to $1,029.99 by midday Tuesday as U.S. prices for GLP-1 obesity drugs dropped sharply, prompting analysts to cut long-term forecasts. Novo Nordisk and Pfizer reported strong weight-loss data for rival drugs this week, intensifying competition. Investors await Lilly’s earnings update Wednesday for signals on pricing, demand, and supply outlooks.
3 February 2026
·····
Pfizer stock drops on obesity-drug data and 2026 outlook — what investors watch next

Pfizer stock drops on obesity-drug data and 2026 outlook — what investors watch next

Pfizer shares fell 3.4% to $25.76 early Tuesday after quarterly results and new Phase 2b obesity drug data. The company reported adjusted Q4 earnings of 66 cents per share on $17.56 billion revenue, both above analyst estimates. Pfizer reaffirmed its 2026 outlook and does not plan share buybacks this year. COVID-19 product sales continued to decline sharply.
3 February 2026
··
GSK share price nears a one-year high ahead of earnings after Wave drug handback and R&D cuts

GSK share price nears a one-year high ahead of earnings after Wave drug handback and R&D cuts

GSK shares edged up 0.1% to 1,926.5 pence Tuesday, nearing a one-year high ahead of its earnings report due Wednesday. The company is cutting about 350 R&D jobs in the UK and U.S. and recently returned rights to the WVE-006 drug candidate to Wave Life Sciences. Investors await CEO Luke Miels’ first major update and signals on cost controls and R&D priorities.
3 February 2026
····
Eli Lilly stock price climbs as obesity-drug forecasts get a reality check before earnings

Eli Lilly stock price climbs as obesity-drug forecasts get a reality check before earnings

Eli Lilly shares rose 1.5% to close near $1,052.70 Monday, recovering from early losses ahead of its earnings report due Wednesday. Analysts have cut long-term forecasts for obesity drugs as prices fall and competition intensifies, with 2030 sales estimates for GLP-1 drugs dropping to about $100 billion. Investors are focused on Lilly’s pricing strategy and demand outlook. The FDA is set to rule on Lilly’s weight-loss pill by April 10.
2 February 2026
····
Novo Nordisk stock heads into earnings week as Wegovy pill scripts top 26,000

Novo Nordisk stock heads into earnings week as Wegovy pill scripts top 26,000

Novo Nordisk Class B shares closed at 369.6 Danish crowns on Friday, down 0.8 crown, as investors awaited the company’s 2025 financial statement set for Feb. 4. U.S. prescriptions for the new Wegovy pill surged to 26,109 in the week ending Jan. 23, up sharply from its launch. Leadership changes in China and rising competition from AstraZeneca add pressure ahead of earnings.
1 February 2026
···
AstraZeneca stock price: NYSE switch, China bets and earnings put AZN in play this week

AstraZeneca stock price: NYSE switch, China bets and earnings put AZN in play this week

AstraZeneca shares closed in London at 135.48 pounds Friday, up 0.65%. The company moves its U.S. listing from Nasdaq to the NYSE on Monday, keeping the AZN ticker. AstraZeneca recently announced a $1.2 billion obesity drug deal with CSPC and pledged $15 billion investment in China by 2030. Investors await full-year results on Feb. 10.
1 February 2026
···
Healthcare stocks hold up as defensive bid lingers; Pfizer, Merck earnings set the tone

Healthcare stocks hold up as defensive bid lingers; Pfizer, Merck earnings set the tone

The Health Care Select Sector SPDR Fund (XLV) rose 0.6% to $154.74 Friday, while the S&P 500 fell 0.43%. Healthcare and consumer staples were the only S&P sectors in positive territory as investors shifted to defensive stocks. Major managed-care shares lagged after a minimal proposed Medicare Advantage rate hike. Pfizer, Merck, and Eli Lilly report earnings next week.
1 February 2026
·····
Johnson & Johnson stock price: JNJ in focus after EU panel backs Akeega expansion

Johnson & Johnson stock price: JNJ in focus after EU panel backs Akeega expansion

Johnson & Johnson shares closed Friday nearly flat at $227.25 after EU advisers backed expanded use of its prostate cancer drug Akeega. The Committee for Medicinal Products for Human Use recommended approval for patients with BRCA1/2 mutations. The final decision rests with the European Commission. Traders are watching Monday’s open and upcoming U.S. economic data.
1 February 2026
···
Amgen stock heads into earnings week after ending Kyowa Kirin eczema pact

Amgen stock heads into earnings week after ending Kyowa Kirin eczema pact

Amgen shares fell 0.3% to $341.88 Friday after disclosing plans to end its 2021 partnership with Kyowa Kirin, which will regain global rights to the eczema drug rocatinlimab. Amgen will report fourth-quarter and full-year earnings after markets close Feb. 3, with investors focused on pipeline priorities following the Kyowa Kirin exit.
31 January 2026
····
Novo Nordisk Class B stock price: Wegovy pill scripts hit 26,000 as earnings week approaches

Novo Nordisk Class B stock price: Wegovy pill scripts hit 26,000 as earnings week approaches

Novo Nordisk Class B shares closed down 0.23% at 369.55 Danish kroner Friday, capping a 7.9% slide over five sessions. U.S. prescriptions for oral Wegovy reached 26,109 in the week ending Jan. 23, after 3,071 in the first four days post-launch. The company faces rising competition in China and awaits EU approval for its MASH drug. Quarterly results and 2026 outlook are due Feb. 4.
31 January 2026
···
AstraZeneca share price: $18.5 billion China obesity-drug deal puts AZN stock in focus for Monday

AstraZeneca share price: $18.5 billion China obesity-drug deal puts AZN stock in focus for Monday

AstraZeneca agreed to license obesity drug candidates from CSPC Pharmaceutical in a deal worth up to $18.5 billion, paying $1.2 billion upfront. AstraZeneca shares rose 0.65% in London, while CSPC shares fell nearly 12% in Hong Kong. The deal gives AstraZeneca rights outside Greater China and includes a once-monthly GLP-1/GIP agonist entering Phase I trials. AstraZeneca will also delist its ADS from Nasdaq and move to the NYSE.
31 January 2026
··
Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Eli Lilly shares rose 1.3% after announcing a $3.5 billion Pennsylvania plant for obesity drugs, helping the Health Care Select Sector SPDR Fund gain 0.6% as the S&P 500 fell. Biotech lagged, with Corcept Therapeutics dropping 10.6% after an FDA rejection. Thermo Fisher slid 2.3% on weak profit guidance. Stryker jumped 4.3% after raising its outlook.
31 January 2026
······
1 … 9 10 11 12 13 … 42

Stock Market Today

  • Hastings Technology Metals Gains After $1M Strategic Investment by Malaco Mining
    June 22, 2026, 11:31 PM EDT. Hastings Technology Metals (ASX:HAS) shares rose 1.54% to AUD 0.33 following a $1.0 million strategic investment from Malaysian miner Malaco Mining Sdn. Bhd. The placement issued approximately 2.74 million shares at AUD 0.365 each, supporting Hastings' rare earth projects in Australia and Thailand. Rare earth elements are vital for electric vehicles, renewable energy, and electronics. Malaco's expertise in mineral exploration and rare earth processing enhances Hastings' balance sheet and potential collaboration opportunities. Hastings' shares have gained 26.92% over the past year, reflecting investor interest in rare earths amid growing global demand.

Latest articles

Amazon Stock Just Got Hit Before Prime Day — AI Spending Fears Are Back

Amazon Stock Just Got Hit Before Prime Day — AI Spending Fears Are Back

23 June 2026
Amazon shares plunged 4.75% to $232.79 as investors questioned whether the company’s massive AI and cloud spending will pay off quickly enough, just ahead of Prime Day—a key test of U.S. consumer demand—with Bank of America projecting $21.6 billion in sales for the event and analysts warning that profit quality could disappoint if shoppers focus on lower-margin essentials.
Keel Shares Hit Record—What’s Next for the Stock

Keel Shares Hit Record—What’s Next for the Stock

23 June 2026
Keel Infrastructure Corp. surged 5.9% to a 52-week high as investors bet its power sites can be converted to AI data-center leases, with shares ending at $6.66 on heavy volume; the stock’s rally now hinges on permits, construction, and landing customer contracts, while upcoming Russell 3000 index inclusion and recent $458 million convertible note financing add both opportunity and dilution risk.
Go toTop